Elsevier

Acta Pharmaceutica Sinica B Template

Write in a clean editor, then format for Acta Pharmaceutica Sinica B in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the Acta Pharmaceutica Sinica B format

Acta Pharmaceutica Sinica B is a peer-reviewed journal published by Elsevier, covering Nanoplatforms for cancer theranostics, Nanoparticle-Based Drug Delivery, RNA Interference and Gene Delivery.

PublisherElsevier
Reference styleNumbered (Elsevier)
Numbered — [1], [2] in the text
[1] A. Smith, B. Jones, C. Lee, A representative article title, Acta Pharmaceutica Sinica B 12 (2023) 45–58.

Formats any DOI in Acta Pharmaceutica Sinica B style. No sign-up.

Publishes research inNanoplatforms for cancer theranostics Nanoparticle-Based Drug Delivery RNA Interference and Gene Delivery Diverse Scientific and Economic Studies Immunotherapy and Immune Responses
ISSN2211-3835
Citation impact (2-yr)8.96
h-index166
i10-index1,934
Total citations141,264
Open accessYes
Top institutions publishing hereChinese Academy of Medical Sciences & Peking Union Medical College
Journal websitewww.journals.elsevier.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Acta Pharmaceutica Sinica B per year

79
2014
90
2015
99
2016
84
2017
123
2018
139
2019
237
2020
352
2021
319
2022
311
2023
353
2024
504
2025

Citation impact of Acta Pharmaceutica Sinica B by publication year

3.7K
2014
10.4K
2015
8.7K
2016
5.1K
2017
10.1K
2018
12.7K
2019
19.6K
2020
26.8K
2021
15.7K
2022
9.5K
2023
6.8K
2024
2.7K
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Acta Pharmaceutica Sinica B

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Canrong Wu, Yang Liu, Yueying Yang et al. · 27 Feb 2020

SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by…

2,476 citations Cite SaveGo to paper →
HIF-1α pathway: role, regulation and intervention for cancer therapy

Georgina N. Masoud, Wěi Li · 7 Jun 2015

Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. It was found that hypoxia (low O2 levels) is a common character in many types…

1,897 citations Cite SaveGo to paper →
Why 90% of clinical drug development fails and how to improve it?

Duxin Sun, Wei Gao, Hongxiang Hu et al. · 11 Feb 2022

Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly emphasizes potency/specificity using structure‒activity-relationship (SAR) but overlooks tissue exposure/selectivity in disease/normal tissues using structure‒tissue exposure/selectivity-relationship (STR), which may mislead the drug candidate selection…

1,632 citations Cite SaveGo to paper →
Insoluble drug delivery strategies: review of recent advances and business prospects

Sandeep Kalepu, Vijaykumar Nekkanti · 25 Aug 2015

The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low…

1,372 citations Cite SaveGo to paper →
Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges

Dinh Ha, Ningning Yang, Venkatareddy Nadithe · 8 Mar 2016

Exosomes are small intracellular membrane-based vesicles with different compositions that are involved in several biological and pathological processes. The exploitation of exosomes as drug delivery vehicles offers important advantages compared to other nanoparticulate drug delivery systems such as liposomes and polymeric nanoparticles; exosomes are non-immunogenic in nature due to similar composition as body׳s own cells.…

1,348 citations Cite SaveGo to paper →

Acta Pharmaceutica Sinica B template — frequently asked questions

How do I write a paper in the Acta Pharmaceutica Sinica B format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Acta Pharmaceutica Sinica B template. When you export, DocuGuru compiles the paper into the official Elsevier format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Acta Pharmaceutica Sinica B use?
Acta Pharmaceutica Sinica B uses Numbered (Elsevier) references, shown as numbered [1], [2] markers in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: [1] A. Smith, B. Jones, C. Lee, A representative article title, Acta Pharmaceutica Sinica B 12 (2023) 45–58.
Do I need to know LaTeX to submit to Acta Pharmaceutica Sinica B?
No. DocuGuru generates the elsarticle LaTeX class and compiles the PDF for you in the background, so you get a Elsevier-ready Acta Pharmaceutica Sinica B document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Acta Pharmaceutica Sinica B template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Acta Pharmaceutica Sinica B format with correct headings, figures, tables, and numbered citations.
Who publishes Acta Pharmaceutica Sinica B?
Acta Pharmaceutica Sinica B is a multidisciplinary journal published by Elsevier. DocuGuru's Acta Pharmaceutica Sinica B template matches Elsevier's official submission format.
Can I export a submission-ready Acta Pharmaceutica Sinica B PDF?
Yes — DocuGuru produces a PDF built with the official Acta Pharmaceutica Sinica B template (the elsarticle class) that is ready to submit to Elsevier, together with the matching LaTeX source files.
How much does the Acta Pharmaceutica Sinica B template cost?
You can start writing in the Acta Pharmaceutica Sinica B template for free. Exporting the final submission-ready Acta Pharmaceutica Sinica B PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Acta Pharmaceutica Sinica B template